S 14506 hydrochlorideHighly potent 5-HT1A agonist; displays unique binding mechanism CAS# 286369-38-8 |
- I-BET-762
Catalog No.:BCC4474
CAS No.:1260907-17-2
- Bromodomain Inhibitor, (+)-JQ1
Catalog No.:BCC1132
CAS No.:1268524-70-4
- I-BET151 (GSK1210151A)
Catalog No.:BCC4476
CAS No.:1300031-49-5
- GSK1324726A
Catalog No.:BCC4038
CAS No.:1300031-52-0
- PFI-1 (PF-6405761)
Catalog No.:BCC2225
CAS No.:1403764-72-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 286369-38-8 | SDF | Download SDF |
PubChem ID | 131905 | Appearance | Powder |
Formula | C24H27ClFN3O2 | M.Wt | 443.94 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 10 mM in ethanol and to 100 mM in DMSO | ||
Chemical Name | 4-fluoro-N-[2-[4-(7-methoxynaphthalen-1-yl)piperazin-1-yl]ethyl]benzamide;hydrochloride | ||
SMILES | COC1=CC2=C(C=CC=C2N3CCN(CC3)CCNC(=O)C4=CC=C(C=C4)F)C=C1.Cl | ||
Standard InChIKey | HWLZKPKZVOLFGK-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C24H26FN3O2.ClH/c1-30-21-10-7-18-3-2-4-23(22(18)17-21)28-15-13-27(14-16-28)12-11-26-24(29)19-5-8-20(25)9-6-19;/h2-10,17H,11-16H2,1H3,(H,26,29);1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Highly potent selective 5-HT1A receptor full agonist (pKi values are 9.0, 6.6, 7.5, 6.6 and < 6.0 for 5-HT1A, 5-HT1B, 5-HT1C, 5-HT2 and 5-HT3 receptors respectively). Possibly binds between the agonist binding site and the G protein interaction switch site, affecting the activation mechanism, and may display positive cooperativity. Anxiolytic following central administration in vivo. |
S 14506 hydrochloride Dilution Calculator
S 14506 hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2526 mL | 11.2628 mL | 22.5256 mL | 45.0511 mL | 56.3139 mL |
5 mM | 0.4505 mL | 2.2526 mL | 4.5051 mL | 9.0102 mL | 11.2628 mL |
10 mM | 0.2253 mL | 1.1263 mL | 2.2526 mL | 4.5051 mL | 5.6314 mL |
50 mM | 0.0451 mL | 0.2253 mL | 0.4505 mL | 0.901 mL | 1.1263 mL |
100 mM | 0.0225 mL | 0.1126 mL | 0.2253 mL | 0.4505 mL | 0.5631 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Erythristemine
Catalog No.:BCN5184
CAS No.:28619-41-2
- 8-Prenylkaempferol
Catalog No.:BCN3311
CAS No.:28610-31-3
- Isoanhydroicaritin
Catalog No.:BCN3879
CAS No.:28610-30-2
- Orientin
Catalog No.:BCN4984
CAS No.:28608-75-5
- CCG-1423
Catalog No.:BCC5581
CAS No.:285986-88-1
- BIRB 796 (Doramapimod)
Catalog No.:BCC2535
CAS No.:285983-48-4
- 22-Dehydroclerosteryl acetate
Catalog No.:BCN5183
CAS No.:28594-00-5
- Docosyl caffeate
Catalog No.:BCN5182
CAS No.:28593-92-2
- Eicosanyl caffeate
Catalog No.:BCN7209
CAS No.:28593-90-0
- Persicogenin
Catalog No.:BCN7744
CAS No.:28590-40-1
- 7-Geranyloxy-6-methoxycoumarin
Catalog No.:BCN5181
CAS No.:28587-43-1
- 4-Benzoyloxy-2-azetidinone
Catalog No.:BCC8696
CAS No.:28562-58-5
- KRN 633
Catalog No.:BCC2544
CAS No.:286370-15-8
- Nigericin sodium salt
Catalog No.:BCC7915
CAS No.:28643-80-3
- Meloscandonine
Catalog No.:BCN5186
CAS No.:28645-27-4
- L-838,417
Catalog No.:BCC7617
CAS No.:286456-42-6
- Multicaulisin
Catalog No.:BCN7840
CAS No.:286461-76-5
- Euphorbiasteroid
Catalog No.:BCN2781
CAS No.:28649-59-4
- Epoxylathyrol
Catalog No.:BCN5382
CAS No.:28649-60-7
- 6'-Amino-3',4'-(methylenedioxy)acetophenone
Catalog No.:BCC8760
CAS No.:28657-75-2
- Fesoterodine Fumarate
Catalog No.:BCC4584
CAS No.:286930-03-8
- Ezatiostat hydrochloride
Catalog No.:BCC4259
CAS No.:286942-97-0
- NCX 4040
Catalog No.:BCC7944
CAS No.:287118-97-2
- PD 180970
Catalog No.:BCC3894
CAS No.:287204-45-9
S 14506: novel receptor coupling at 5-HT(1A) receptors.[Pubmed:11166326]
Neuropharmacology. 2001 Mar;40(3):334-44.
S 14506 is chemically related to the inverse agonist at 5-HT(1A) receptors, spiperone, but S 14506 behaves as one of the most potent agonists known at these receptors, both in vitro and in vivo. In hippocampal membranes, the specific binding of [(3)H]-S 14506 (K(d)=0.79+/-0.2 nM; B(max)=400+/-32 fmol/mg protein) to 5-HT(1A) receptors resembled that of an antagonist in that it was increased by GppNHp, whereas GppNHp reduced the binding of the classic agonist [(3)H]-8-OH-DPAT (K(d)=1.5+/-0.5 nM; B(max)=303+/-20 fmol/mg protein). Manganese, magnesium and calcium reduced the binding of [(3)H]-S 14506 to 5-HT(1A) receptors whereas the binding of [(3)H]-8-OH-DPAT was increased. Further, sodium markedly reduced the binding of [(3)H]-8-OH-DPAT, without affecting the binding of [(3)H]-S 14506. [(3)H]-S 14506 also bound with high affinity to h 5-HT(1A) receptors stably expressed in membranes of CHO cells (K(d)=0.13+/-0.05 nM; B(max)=2.99+/-0.60 pmol/mg protein): the B(max) was double that of [(3)H]-8-OH-DPAT. GppNHp strongly decreased [(3)H]-8-OH-DPAT binding but scarcely changed [(3)H]-S 14506 binding; calcium, magnesium and manganese had little effect on [(3)H]-S 14506 binding in CHO cells. Antagonists (WAY 100635, WAY 100135) and inverse agonists (spiperone and metitepine) displaced [(3)H]-S 14506 binding with high affinity and Hill slopes close to unity, whereas agonists (5-HT and 5-CT) displayed low affinity with low Hill slopes: partial agonists (buspirone, ipsapirone) showed intermediate properties. In fusion proteins of h 5-HT(1A) receptors with G(ialpha1) the compound potently increased high-affinity GTPase, with a steeper Hill slope than for 5-HT, which may indicate positive cooperativity. The maximum response for S 14506 in these assays was equivalent to 5-HT, indicating it to be a full agonist.In molecular modelling studies, using a three-site model of the 5-HT(1A) receptor, S 14506 spanned between the 5-HT recognition site and the "arginine switch" (DRY microdomain) postulated to activate the interaction of the receptor with the G protein. Thus it is possible to synthesise ligands at G-protein-coupled receptors which are highly potent agonists, but which are structurally related to inverse agonists and show some features of antagonist/inverse agonist binding.
Atypical in vitro and in vivo binding of [3H]S-14506 to brain 5-HT1A receptors.[Pubmed:9503258]
J Neural Transm (Vienna). 1997;104(10):1059-75.
The tritiated derivative of the potent 5-HT1A receptor agonist S-14506 inverted question mark1[2-(4-fluorobenzoylamino)ethyl]-4-(7-methoxynaphtyl)pipera zine inverted question mark was tested for its capacity to selectively label the serotonin 5-HT1A receptors both in vitro in the rat and the mouse brain, and in vivo in the mouse. In vitro studies showed that the pharmacological profile and the distribution of [3H]S-14506 specific binding sites (Kd = 0.15 nM) in different brain regions matched perfectly those of the prototypical 5-HT1A receptor ligand [3H]8-OH-DPAT. However, in the three regions examined (hippocampus, septum, cerebral cortex), the density of [3H]S-14506 specific binding sites was significantly higher (+66-90%) than that found with [3H]8-OH-DPAT. Whereas the specific binding of [3H]8-OH-DPAT was markedly reduced by GTP and Gpp(NH)p and increased by Mn2+, that of [3H]S-14506 was essentially unaffected by these compounds. In addition, the alkylating agent N-ethylmaleimide was much less potent to inhibit the specific binding of [3H]S-14506 than that of [3H]8-OH-DPAT. Measurement of in vivo accumulation of tritium one hour after i.v. injection of [3H]S-14506 to mice revealed marked regional differences, with about 2.5 times more radioactivity in the hippocampus than in the cerebellum. Pretreatment with 5-HT1A receptor ligands prevented tritium accumulation in the hippocampus but not in the cerebellum. Autoradiograms from brain sections of injected mice confirmed the specific in vivo labeling of 5-HT1A receptors by [3H]S-14506, therefore suggesting further developments with derivatives of this molecule for positron emission tomography in vivo in man.